Company · founded 2011
Tetra Therapeutics (United States)
Grand Rapids, United States · tetratherapeutics.com
- Citations, last 5 years
- 6
- Works, last 5 years
- 2
- h-index
- 35
- Scientists listed
- 1
- Grants since 2016
- 10
Grants received
2025–2026 · research · R43
Title: New Clinical Biomarkers for GM1 Gamgliosidosis
Jillian R Brown · Tetra Therapeutics (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Testing Novel Advancements to Recombinant Heparin Production
Charles Alexander Glass · Tetra Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Title: Development and Validation of Therapy for GM1 Gangliosidosis
Jillian R Brown · Tetra Therapeutics (United States) · funded by National Institutes of Health
2022–2024 · research · R43
Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad
Charles Alexander Glass · Tetra Therapeutics (United States) · funded by National Institutes of Health
2019–2020 · research · R44
PDE4D PET Ligand
Mark E Gurney · Tetra Therapeutics (United States) · funded by National Institutes of Health
2017 · research · R44
BPN14770 Safety and Cognitive Effect in Young and Elderly Subjects
Mark E Gurney · Tetra Therapeutics (United States) · funded by National Institutes of Health
2016–2017 · research · R44
BPN14770 Safety and Cognitive Effect in Young and Elderly Subjects
Mark E Gurney · Tetra Therapeutics (United States) · funded by National Institutes of Health
2015–2020 · research · R44
PDE4D PET Ligand
Mark E Gurney · Tetra Therapeutics (United States) · funded by National Institutes of Health
2011–2020 · research · R44
Phosphodiesterase-4B (PDE4B) Inhibitors for Alzheimer's Disease
Mark E Gurney · Tetra Therapeutics (United States) · funded by National Institutes of Health
2011–2021 · research · R44
Phosphodiesterase-4B (PDE4B) Inhibitors for Psychiatric Disease
Mark E Gurney · Tetra Therapeutics (United States) · funded by National Institutes of Health
